Oncolytics Biotech Advances Colorectal Cancer Trial with FDA Meeting
Event summary
- Oncolytics Biotech plans to hold a Type D meeting with the FDA in August 2026 to discuss a potential registrational pathway for its REO 033 trial.
- Part B of the REO 033 study will be a randomized study designed to support both accelerated and full approval for pelareorep in RAS-mutant MSS colorectal cancer.
- Half of the planned clinical sites for the REO 033 trial will be activated by the end of July 2026, with more than 20 patients pre-identified across participating centers.
The big picture
Oncolytics Biotech is advancing its pelareorep immunotherapy through a strategic regulatory interaction with the FDA, aiming to streamline the path to approval. The company's approach of integrating Part B into the existing REO 033 trial design could accelerate the development process while maintaining scientific rigor. This move comes amid growing interest in immunotherapies for colorectal cancer, particularly those targeting RAS-mutant MSS tumors, which have historically had limited treatment options.
What we're watching
- Regulatory Pathway
- Whether the FDA will approve the addition of Part B to the REO 033 trial design, which could significantly reduce development timelines.
- Trial Execution
- The pace at which Oncolytics can activate remaining clinical sites and enroll patients in Part A of the REO 033 study.
- Clinical Efficacy
- How initial tumor response data from Part A of the REO 033 study will impact the potential registrational pathway for pelareorep.
Related topics